Spero Therapeutics Inc

NASDAQ:SPRO   12:10:53 PM EDT
12.46
-0.35 (-2.73%)
Products, Regulatory, Earnings Announcements

Spero Therapeutics Announces Positive Topline Results From Phase 3 Adapt-Po Clinical Trial Of Oral Tebipenem HBR In Complicated Urinary Tract Infection And Acute Pyelonephritis

Published: 09/08/2020 11:54 GMT
Spero Therapeutics Inc (SPRO) - Spero Therapeutics Announces Positive Topline Results From Its Phase 3 Adapt-po Clinical Trial of Oral Tebipenem Hbr in Complicated Urinary Tract Infection and Acute Pyelonephritis.
Spero Therapeutics Inc - Intends to Complete NDA Submission for U.S. Regulatory Approval of Tebipenem Hbr in Q2 2021.
Spero - Comparative Safety Data From 1,372 Hospitalized Adults Suggest Tebipenem Hbr Well-tolerated, With Safety Profile Similar to Ertapenem.
Revenue is expected to be $3.75 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $3.75 Million
Next Quarter EPS Guidance is expected to be -$0.66

More details on our Analysts Page.